The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD

Summary

To determine the efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BID vs Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions

• Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Salmeterol/Fluticasone Propionate

Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks

Sponsors & Collaborators

• Shanghai Zhongshan Hospital

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• The First Affiliated Hospital with Nanjing Medical University

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Xinqiao Hospital of Chongqing

  collaborator OTHER

• Qingdao University

  collaborator OTHER

• Armed Police Medical college Affiliated Hospital

  collaborator UNKNOWN

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Henan Provincial People's Hospital

  collaborator OTHER

• Fudan University

  lead OTHER

Principal Investigators

• Chunxue C BAI, Doctor · Fudan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

79 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-07-31

Primary Completion

2011-02-28

Completion

2011-10-31

Countries

• China

Study Locations